|
|
|
Technology |
Technology :: IRSImmunoregulatory sequences (IRS)Our proprietary technology platform includes immunoregulatory sequences (IRS), which are short DNA sequences that specifically inhibit the Toll-like Receptors (TLR) associated with autoimmune and inflammatory diseases. TLRs are key receptors of the innate immune system that can induce strong inflammatory responses. Our TLR inhibitors have demonstrated broad potential in multiple autoimmune diseases models, such as lupus, inflammatory skin disorders, and rheumatoid arthritis. These first-in-class endosomal TLR inhibitors specifically target two types of immune cells, B cells and Plasmacytoid DC (PDC) that selectively express TLR7 and TLR9. These receptors play a key role in the overproduction of interferon alpha by PDC and in the presence of anti-nuclear autoantibodies generated by B cells, which are hallmarks of some autoimmune diseases such as lupus. Our TLR inhibitors only target pathogenic interferon and autoantibodies and do not inhibit all sources of interferon nor do they affect all antibody responses from B cells. This suggests that these TLR inhibitors would not cause broad immunosuppression.
|
|
 |
